| REVIEW ARTICLE |
|
| Year : 2011 | Volume
: 8
| Issue : 1 | Page : 32-70 |
|
|
Management of chronic hepatitis B
Rohit Goyal, Subrat K Acharya
Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India
Correspondence Address:
Subrat K Acharya
Department of Gastroenterology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi - 110 029
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0972-9747.190079
|
|
|
Hepatitis B virus (HBV) is the most important cause of chronic liver disease and hepatocellular carcinoma in India. During the past three decades, considerable advances in the diagnosis and treatment of HBV infection have been achieved. However, despite the remarkable improvements, medical management for HBV induced cirrhosis, and liver cancer remains unsatisfactory. In fact, it is becoming increasingly clear that as of now, there is no "cure" for hepatitis B infection. Management of chronic hepatitis B has changed considerably; currently, emphasis is in identifying and treating patients at high risk of disease progression since effective antiviral therapy arrests disease progression, reduces complications and can potentially reverse liver damage if given for sufficient duration. The treatment should be initiated with drugs that have high potency and high genetic barrier to resistance, and compliance should be ensured once decision to treat is initiated. Resistant patients are difficult to treat and preferably combination treatment with high potency and high genetic barrier drugs should be used to avoid treatment failure. Close monitoring of both treated and untreated patients for disease progression should be done, and early intervention is required to prevent complications in those who show progression over time.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
